#ACC21: Re­gen­eron's Evkeeza shows promise in curb­ing high triglyc­erides, but will ge­net­ic dis­par­i­ties lim­it use?

When Re­gen­eron scored an ear­ly ap­proval for lipid low­er­ing an­ti­body Evkeeza back in Feb­ru­ary, the drug­mak­er cracked open a new path­way to low­er ab­nor­mal­ly high …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER